LITTLE ROCK, AK, Nov. 19, 2013 /CNW/ - Vivione Biosciences Corporation
(TSXV:VBI) today announced a new three-year Cooperative Research and
Development Agreement (CRADA) with the Food and Drug Administration's
(FDA) National Center for Toxicological Research (NCTR). The focus of
the CRADA is to expand the capability of Vivione's RAPID-B™ diagnostic
The Vivione RAPID-B™ system is a revolutionary high-performance
diagnostic system for detecting bacterial pathogens. Unlike other
systems that look at a gross response of an entire sample to provide
information, the RAPID-B™ system looks individually at each bacterium's
physical properties (including size, shape, and transparency) and
analyzes unique responses to probes and DNA dyes. RAPID-B™ allows the
testing of food products in seven hours or less, including sample
preparation versus other commercial systems that take up to 48 hours to
provide results. Moreover, single shift results are achieved without
the need for labor intensive sample preparation steps including
centrifugation and immuno-magnetic separation.
The implication for the general public is that RAPID-B™ can yield better
and faster micro results than current methods, making food and consumer
products safer. "New research contemplated under the CRADA will augment
the present RAPID-B™ assays for food safety," said Ted Moskal,
Vivione's President and Chief Science Officer. "We are developing new
methods that can rapidly identify the pathogens responsible for disease
outbreaks beyond food-borne illnesses." Moskal further explained that
the new research will expand to include the tiniest disease-causing
agents known to man, particularly viruses and prions, for which there
are no current detection methods available.
CEO of Arkansas Research Alliance, Jerry Adams said, "I'm very pleased
NCTR-FDA has entered into a CRADA with Vivione. The relationship
between government research and commercial entities is important for
the development of new technologies and employment. The development of
better, faster and less expensive diagnostics is both key to
maintaining a safer food supply and also to yield better outcomes for
identification of infectious disease in clinical settings. The Research
Alliance is hopeful that this collaboration will lead to the
development of new diagnostics, the growth of biosciences in the state
and more knowledge-based jobs."
In both clinical as well as food safety settings, very low pathogen
levels can cause human morbidity and mortality, particularly in such
susceptible populations as the elderly, children and immune-suppressed
individuals. RAPID-B™ has the ability to detect extremely low levels of
infectious agents in complex biological matrices, thus potentially
increasing early diagnoses, specifically in time-critical situations.
Overall the research under the CRADA will strive to expand the utility
of RAPID-B™ to a greater variety of locations and contexts, including
field settings and clinical venues. According to Moskal, the goal is
to design and test new RAPID-B™ assays capable of real-time detection
of diverse pathogens directly from the native sample thus reducing the
steps associated with typical sample preparations and yielding faster,
simpler and cost-effective diagnostic tests.
Arkansas Governor Beebe said, "The State of Arkansas applauds the new
Cooperative Research and Development Agreement between the FDA National
Center for Toxicological Research and Vivione Biosciences.
Public-Private partnerships for research are critical to the
development of new products that benefit the public and keep America
competitive. The biotech sector is increasingly more important to the
generation of knowledge-based jobs. We're so proud that both
organizations are located in the state of Arkansas."
Vivione's business is centered on the commercialization of the RAPID-B™
system, which is an integrated system of hardware, software and
chemical reagents that tests bacteria in key environments. This
technology could have potentially diverse applicability from food
safety to clinical diagnostics, by identifying and quantifying
microorganism levels more rapidly and with greater precision than
currently employed techniques.
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
In particular,this press release contains forward-looking information
relating to the commercialization and anticipated effectiveness of
RAPID-B.. Readers are cautioned to not place undue reliance on
forward-looking statements. The statements in this press release are
made as of the date of this release and, except as required by
applicable law, Vivione does not undertake any obligation to publicly
update or to revise any of the included forward-looking statements,
whether as a result of new information, future events or otherwise.
Vivione undertakes no obligation to comment on analyses, expectations
or statements made by third-parties in respect of Vivione, or its
financial or operating results or (as applicable), their securities.
SOURCE: Vivione Biosciences Inc.
For further information:
Vivione Biosciences Inc.
Chief Executive Officer
Tel: (214) 886-5733